Ipratropium nebuliser (500 mcg/2 ml): Supply issue

Supply issue Active

Rex Medical have advised of a supply issue with ipratropium nebuliser solution (Pharmacode 2154307).

Reason for the issue

Due to a significant increase in demand, stock levels of ipratropium nebuliser solution (Pharmacode 2154307) are depleted. There have been some technical issues at the manufacturing plant which have slowed the resupply of this product.

Schedule listing for ipratropium nebuliser solution(external link)

Alternative product

Pharmac and Rex Medical have sourced an alternative product. This product was listed in the Schedule from 5 August 2022 as a section 29 medicine. Supply of the alternative is unlikely to be available before late August 2022.

Rex Medical is allocating the remaining stock of the registered product to help distribute the remaining supply as fairly as possible. 

Listed alternative for ipratropium bromide: 

  • Presentation: Nebuliser soln, 250 mcg per ml,2 ml ampoule
  • Brand: Accord
  • Pack Size: 20
  • Subsidy and price: $28.20 (ex-man., ex. GST)
  • Pharmacode: 2643154

Schedule listing for ipratropium bromide(external link)

Information for phamacists

This listing will not appear in the Online Schedule until it is updated for 1 September 2022.

RxOne users: the changes will be automatically updated by RxOne from the effective date (5 August 2022). 

TONIQ users: the changes will automatically be updated in Toniq medicine databases from the effective date (5 August 2022). 

Please note that the Ministry of Health Sector Operations Group will be able to process these claims in August 2022 in the normal claim cycle.

Prescribing and supplying a medicine under section 29

Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – e.g., doctors. 

We know supplying a medicine under section 29 is not ideal. This is the only alternative available to ensure people can continue to access treatment.  

We apologise for any inconvenience this causes. 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website(external link)

What patients need to know about section 29 medicines – Health Navigator website(external link)

Expected resupply

Rex Medical expects to be able to return to normal supply with the registered product by November 2022.

Who to contact

If you have questions about the funding for this product, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is. 

About Pharmac's role in supply management